Kite Pharma, Inc. Insider Trading for September 2015
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Kite Pharma, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in Kite Pharma, Inc. for September 2015.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Option Exercise | M | 1.35 | 10,000 | 13,500 | 375,394 | |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 56.70 | 3,640 | 206,388 | 75,507 | 79.1 K to 75.5 K (-4.60 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 55.91 | 3,560 | 199,040 | 79,147 | 82.7 K to 79.1 K (-4.30 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Sell | S | 54.73 | 2,800 | 153,244 | 82,707 | 85.5 K to 82.7 K (-3.27 %) |
| Sep 30 2015 | KITE | Kite Pharma, Inc. | BUTITTA CYNTHIA M | COO and CFO | Buy | M | 1.35 | 10,000 | 13,500 | 85,507 | 75.5 K to 85.5 K (+13.24 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Option Exercise | M | 6.89 | 9,000 | 62,010 | 130,000 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 64.69 | 4,440 | 287,224 | 6,342 | 10.8 K to 6.3 K (-41.18 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Sell | S | 63.99 | 4,560 | 291,794 | 10,782 | 15.3 K to 10.8 K (-29.72 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Wiezorek Jeffrey | VP Clinical Develop ... | Buy | M | 6.89 | 9,000 | 62,010 | 15,342 | 6.3 K to 15.3 K (+141.91 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Option Exercise | M | 1.35 | 9,567 | 12,915 | 152,165 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 65.28 | 128 | 8,356 | 2,941 | 3.1 K to 2.9 K (-4.17 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 64.66 | 5,165 | 333,969 | 3,069 | 8.2 K to 3.1 K (-62.73 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Sell | S | 63.97 | 4,274 | 273,408 | 8,234 | 12.5 K to 8.2 K (-34.17 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Sproule Rizwana F | VP Regulatory Affai ... | Buy | M | 1.35 | 9,567 | 12,915 | 12,508 | 2.9 K to 12.5 K (+325.30 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 17.00 | 645 | 10,965 | 35,168 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Option Exercise | M | 0.70 | 5,500 | 3,850 | 113,125 | |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 64.66 | 3,181 | 205,683 | 2,198 | 5.4 K to 2.2 K (-59.14 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Sell | S | 63.98 | 2,964 | 189,637 | 5,379 | 8.3 K to 5.4 K (-35.53 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 17.00 | 645 | 10,965 | 8,343 | 7.7 K to 8.3 K (+8.38 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Roberts Margo R | Chief Scientific Of ... | Buy | M | 0.70 | 5,500 | 3,850 | 7,698 | 2.2 K to 7.7 K (+250.23 %) |
| Sep 17 2015 | KITE | Kite Pharma, Inc. | Humer Franz B | Director | Option Exercise | A | 56.12 | 20,000 | 1,122,400 | 20,000 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,384 | 50,876 | 269,200 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 316 | 2,177 | 276,584 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 7,384 | 406,120 | 6,904 | 14.3 K to 6.9 K (-51.68 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,384 | 50,876 | 14,288 | 6.9 K to 14.3 K (+106.95 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 316 | 17,380 | 6,904 | 7.2 K to 6.9 K (-4.38 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 316 | 2,177 | 7,220 | 6.9 K to 7.2 K (+4.58 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Option Exercise | M | 0.38 | 9,000 | 3,420 | 105,000 | |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 52.90 | 269 | 14,230 | 1,888 | 2.2 K to 1.9 K (-12.47 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 52.34 | 3,712 | 194,286 | 2,157 | 5.9 K to 2.2 K (-63.25 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Sell | S | 51.36 | 5,019 | 257,776 | 5,869 | 10.9 K to 5.9 K (-46.10 %) |
| Sep 03 2015 | KITE | Kite Pharma, Inc. | Better Marc | VP, Product Science ... | Buy | M | 0.38 | 9,000 | 3,420 | 10,888 | 1.9 K to 10.9 K (+476.69 %) |